Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F et al (2023) Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. NPJ Breast Cancer 9(1):51

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826

Article  CAS  PubMed  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S (2021) Development and validation of a tool integrating the 21-gene recurrence score and clinical–pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol 39(6):557–564

Article  CAS  PubMed  Google Scholar 

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL et al (2021) 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336–2347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, Guerrero Paez C, Mol L, Beeker A, Beelen K et al (2024) Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. Nature 636(8042):474–480

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Dieras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M et al (2024) Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 42(9):994–1000

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942–950

Article  CAS  PubMed  Google Scholar 

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA et al (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116–124

Article  PubMed  Google Scholar 

Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F et al (2014) A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 50(2):277–289

Article  CAS  PubMed  Google Scholar 

Schrijver W, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ (2018) Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst 110(6):568–580

Article  PubMed  Google Scholar 

Dowling GP, Keelan S, Cosgrove NS, Daly GR, Giblin K, Toomey S, Hennessy BT, Hill ADK (2024) Receptor discordance in metastatic breast cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Res Treat 207(3):471–476

Article  PubMed  PubMed Central  Google Scholar 

Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM et al (2021) Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov 11(11):2796–2811

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cejalvo JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, Burgues Gasion O, Pare L, Antolin S, Martinello R, Blancas I, Adamo B et al (2017) Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res 77(9):2213–2221

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J (2014) Breast cancer during follow-up and progression—a population based cohort on new cancers and changed biology. Eur J Cancer 50(17):2916–2924

Article  CAS  PubMed  Google Scholar 

Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381–7388

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N et al (2022) Tumor genomic testing for > 4,000 men with metastatic castration-resistant prostate cancer in the Phase III trial PROfound (olaparib). Clin Cancer Res 28(8):1518–1530

Article  CAS  PubMed  Google Scholar 

King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC et al (2016) Prognostic impact of 21-gene recurrence score in patients with Stage IV breast cancer: TBCRC 013. J Clin Oncol 34(20):2359–2365. https://doi.org/10.1200/JCO.2015.63.1960

Article  CAS  PubMed  PubMed Central  Google Scholar